Press-release for stocks related to trial for nktr

Prices are updated after-hours

tags : Trial symbols : Nktr

save search

Lilly, Nektar Stumble in Phase II Lupus Trial
Published: 2023-02-24 (Crawled : 16:00) - biospace.com/
NKTR | News | $1.265 -4.17% -4.35% 4.7M

Health Technology

| -58.11% | O: -40.2% H: 2.82% C: -15.82%
lupus trial

First-Ever Computationally-Designed Antibody Enters Clinical Trials
Published: 2022-04-05 (Crawled : 20:00) - biospace.com/
NKTR | News | $1.265 -4.17% -4.35% 4.7M

Health Technology

| -78.36% | O: 0.0% H: 1.31% C: -1.57%
trials antibody trial designation

First-Ever Computationally Designed Antibody, Created by Biolojic Design, Entering Human Clinical Trial In Cancer Patients
Published: 2022-04-05 (Crawled : 11:00) - prnewswire.com
NKTR | News | $1.265 -4.17% -4.35% 4.7M

Health Technology

| -78.36% | O: 0.0% H: 1.31% C: -1.57%
trial cancer designation antibody

Nektar Left Reassessing After Canceled Melanoma Trials
Published: 2022-03-15 (Crawled : 15:30) - biospace.com/
NKTR | News | $1.265 -4.17% -4.35% 4.7M

Health Technology

| -75.2% | O: -21.0% H: 13.67% C: 13.42%
als trials trial cel

Two Melanoma Trials Fall as BMS and Nektar Report Disappointing Results
Published: 2022-03-14 (Crawled : 14:30) - biospace.com/
NKTR | News | $1.265 -4.17% -4.35% 4.7M

Health Technology

| -88.79% | O: -54.79% H: 0.0% C: 0.0%
als trials trial report results sap

Nektar Therapeutics to Host Webcast Conference Call for Analysts & Investors Following Announcement of Update from Bristol-Myers Squibb and Nektar on the PIVOT-IO-001 Phase 3 Trial
Published: 2022-03-14 (Crawled : 12:30) - biospace.com/
NKTR | News | $1.265 -4.17% -4.35% 4.7M

Health Technology

| -88.79% | O: -54.79% H: 0.0% C: 0.0%
io-001 announcement trial conference therapeutics phase 3

Bristol Myers Squibb and Nektar Announce Update on Phase 3 PIVOT IO-001 Trial Evaluating Bempegaldesleukin (BEMPEG) in Combination with Opdivo (nivolumab) in Previously Untreated Unresectable or Metastatic Melanoma
Published: 2022-03-14 (Crawled : 12:30) - biospace.com/
BMY | $48.93 1.3% 0.0% 10M

Health Technology

| -28.14% | O: 1.26% H: 0.0% C: 0.0%
NKTR | News | $1.265 -4.17% -4.35% 4.7M

Health Technology

| -88.79% | O: -54.79% H: 0.0% C: 0.0%
io-001 opdivo trial phase 3 nivolumab

Regulatory T-cells (Tregs) Therapies Market - Future Pipeline/Clinical Trial Analysis and Revenue Forecast Snapshot
Published: 2022-02-16 (Crawled : 08:00) - prnewswire.com
LLY | News | $726.31 -2.63% -0.04% 3.5M

Health Technology

| 197.86% | O: -0.52% H: 1.83% C: 1.24%
NKTR | News | $1.265 -4.17% -4.35% 4.7M

Health Technology

| -88.91% | O: -0.27% H: 1.26% C: 0.36%
trial cel t-cell therapy

Nykode Therapeutics announces completion of patient enrollment in its Phase 2 trial of VB10.16 in combination with atezolizumab for the treatment of advanced cervical cancer
Published: 2022-02-11 (Crawled : 06:00) - globenewswire.com
NKTR | News | $1.265 -4.17% -4.35% 4.7M

Health Technology

| -88.88% | O: -1.12% H: 0.0% C: 0.0%
vb10 treatment phase 2 trial therapeutics cancer enroll

Exelixis Announces Initiation of Phase 1b Trial Evaluating XL092 in Combination with Immuno-oncology Therapies in Patients with Advanced Solid Tumors
Published: 2021-12-15 (Crawled : 15:00) - biospace.com/
BMY | $48.93 1.3% 0.0% 10M

Health Technology

| -17.78% | O: 0.18% H: 2.11% C: 1.66%
NKTR | News | $1.265 -4.17% -4.35% 4.7M

Health Technology

| -90.22% | O: 0.16% H: 2.52% C: 2.05%
EXEL | $22.51 0.09% 0.09% 2.3M

Health Technology

| 32.47% | O: -0.59% H: 5.8% C: 5.68%
xl092 solid tumors phase 1b trial phase 1 phase 2b

PharmaJet Partner Nykode Therapeutics Announces Phase 1/2 Clinical Trial With Next Generation DNA-Based COVID-19 Vaccine Candidates
Published: 2021-12-14 (Crawled : 15:00) - biospace.com/
NKTR | News | $1.265 -4.17% -4.35% 4.7M

Health Technology

| -89.82% | O: 2.3% H: 3.69% C: 1.77%
covid-19 trial therapeutics covid phase 1 vaccine phase 2

Celsion Corporation Adds Key Resources to its Vaccine Development Initiative and Clinical Trial Capabilities
Published: 2021-10-05 (Crawled : 14:15) - biospace.com/
NKTR | News | $1.265 -4.17% -4.35% 4.7M

Health Technology

| -93.15% | O: 0.06% H: 1.55% C: -5.41%
vaccine trial

Exelixis Announces Clinical Trial Collaboration and Supply Agreement with Bristol Myers Squibb to Evaluate XL092 in Combination with Immuno-oncology Therapies in Advanced Solid Tumors
Published: 2021-06-14 (Crawled : 17:00) - biospace.com/
BMY | $48.93 1.3% 0.0% 10M

Health Technology

| -27.34% | O: -0.03% H: 0.19% C: -0.04%
NKTR | News | $1.265 -4.17% -4.35% 4.7M

Health Technology

| -92.96% | O: 0.62% H: 2.31% C: -0.23%
EXEL | $22.51 0.09% 0.09% 2.3M

Health Technology

| -2.0% | O: 0.48% H: 1.08% C: -1.43%
solid tumors collaboration trial therapy

Abingworth's $582 Million Co-Development Fund Will Propel Late-Stage Trials
Published: 2021-05-10 (Crawled : 14:00) - biospace.com/
NKTR | News | $1.265 -4.17% -4.35% 4.7M

Health Technology

| -93.83% | O: 0.35% H: 0.4% C: -2.18%
trial